Skip to main content

Regeneron: It’s All Riding On Dupixent

Shares of biotechnology giant Regeneron Pharmaceuticals ( REGN ) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded from a neutral to an overweight, with an$446 price target. The bullish call, which comes just a few days after the drug maker released soft guidance for 2017, argues that “anticipated approvals and a deep pipeline should drive long-term value” for this closely-watched drug stock. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.